Lung Cancer Screening Market By Type (Low-dose computed tomography (LDCT), X-ray), By Age group (50 and older, Below 50), By End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Lung Cancer Screening Market

The U.S. Preventive Services (USPSTF) recommends annual screening for lung cancer by using low-dose computed tomography (LDCT), in adults aged between 50-80 years who have a smoking history or currently smoke. Lung cancer occurs in people who consume tobacco, are exposed to asbestos, and due to family history of lung cancer. Lung cancer typically starts in the parts of lung, such as alveoli or bronchioles. Small cell lung cancer and non-small cell lung cancer are the two main types of lung cancer. In small cell lung cancer, malignant cells are small and round when observed under microscope. However, in non-small cell lung cancer, malignant cells are larger under a microscope. Thus, early stage screening for lung cancer may reduce the risks associated with the caner spread.

Factors that drive the growth of global lung cancer screening market include, increase in prevalence of non-small cell lung cancer, rise in obesity, lifestyle changes, and rise in smoking population that are more prone to develop lung cancer. For instance, according to the American Society of Clinical Oncology (ASCO), about 235,000 adults in U.S. were affected by lung cancer in 2020. In addition, technological innovations in screening methods and rise in R&D activities by market key players for developing advanced products contribute towards the growth of the lung cancer screening market share. Furthermore, increase in awareness regarding early stage screening and its benefits is the key factor expected to create lucrative growth opportunities for lung cancer screening market size during the forecast period.

However, lack of awareness and limited access to screening methods in low cost countries hampers the growth of the lung cancer screening industry.

Depending on type, the lung cancer screening market analysis is bifurcated into low-dose computed tomography (LDCT) and X-ray. The low-dose computed tomography (LDCT) exhibited the highest growth in 2021, and is expected to register fastest growth during the forecast period owing to increase in awareness about screening methods in developed countries and growing adoption of low-dose computed tomography in the screening of lung cancer.

On the basis of age group, the market is segmented into 50 and older and below 50. The 50 and older segment exhibited the highest growth in 2021, and is expected to register a fastest CAGR during the forecast, owing to rise in prevalence of non-small cell lung cancer in patients aged over 50.

On the basis of end user, the lung cancer screening industry is classified into hospitals, diagnostic centers, and others. The diagnostic centers segment dominated the market in 2021 and is expected to remain dominant during the forecast period. The market growth of this segment driven by growing preference of patients towards diagnostic centers for cancer screening. However, others segment expected to exhibit fastest growth during the forecast period, owing to adoption of cancer diagnostic equipment in cancer research institutes.

Region-wise, North America had the highest lung cancer screening market share in 2021, and is expected to maintain its lead during the forecast period, owing to growing cases of lung cancer and increase in adoption of technologically advanced screening solutions. Moreover, North America advances due to well established healthcare infrastructure. However, Asia-Pacific is expected to register a highest CAGR during the lung cancer screening market forecast period, owing to increasing smoking population and accessibility to advanced screening solutions in the healthcare facility.

KEY FINDINGS OF THE STUDY

By type, the low-dose computed tomography (LDCT) segment dominated the market in 2021.

By age group, the 50 and older dominated the market in 2021, and is expected to continue this lung cancer screening market trends during the forecast period

By end user, the diagnostic centers dominated the market in 2021

Region-wise, North America generated the largest revenue share in 2021, however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Overview

The global lung cancer screening market was valued at $879.59 million in 2021, and is projected to reach $1,853.04 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.

Lung cancer screening refers to methods for detecting early lung cancer before they cause symptoms at a point where they are more likely to be cured. Lung cancer is the most common type of cancer that begins in the lungs. Cigarette smoking is the main cause of lung cancer. Based on the microscopic appearance, the tumor cells are classified into small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC). The recommended screening test for lung cancer are low-dose computed tomography and X-ray.

The growth of global lung cancer screening market is majorly driven by alarming increase in prevalence of lung cancer across the globe, increase in smoking population, and technological innovations in screening methods. For instance, the American Society of Clinical Oncology (ASCO) in 2020, stated that the lung cancer is the 2nd most common type of cancer in women and men. In addition, rise in efforts taken by government for early stage detection of lung cancer propels the growth of the market.

Furthermore, rise in awareness regarding early stage screening for lung cancer and surge in the incidences of lung cancer are responsible to increase the demand for effective screening tests. These factors are expected to create growth opportunities for the lung cancer screening market during the forecast period.

However, high cost of screening tests and lack of awareness regarding screening techniques in the developing countries are the factors expected to hamper the growth of the market.

The lung cancer screening market is segmented into type, age group, end user, and region. By type, the market is categorized into low-dose computed tomography (LDCT) and X-ray. On the basis of age group, the market is segregated into 50 and older and below 50. By end user, the market is classified into hospitals, diagnostic centers, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global lung cancer screening market are Canon Medical Systems U.S. Inc., Eon Health, Fujifilm Holdings Corporation, General Electric Company (GE Healthcare), Koninklijke Philips N.V., Medtronic Plc, Microsoft Corporation (Nuance Communications, Inc.), Penrad Technologies Inc., Siemens Ag, and Volpara Solutions Limited.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the lung cancer screening market analysis from 2021 to 2031 to identify the prevailing lung cancer screening market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the lung cancer screening market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global lung cancer screening market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Volpara Solutions Limite

Scope of Lung Cancer Screening Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Low-dose computed tomography (LDCT)

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 X-ray

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 50 and older

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Below 50

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospitals

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.2.4 Hospitals Lung Cancer Screening Market by Type

6.2.4.1 Public Market size and forecast, by region

6.2.4.2 Private Market size and forecast, by region

6.3 Diagnostic Centers

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.4 Others

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Type

7.2.3 North America Market size and forecast, by Age group

7.2.4 North America Market size and forecast, by End User

7.2.4.1 North America Hospitals Lung Cancer Screening Market by Type

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Type

7.2.5.1.2 Market size and forecast, by Age group

7.2.5.1.3 Market size and forecast, by End User

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Type

7.2.5.2.2 Market size and forecast, by Age group

7.2.5.2.3 Market size and forecast, by End User

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by Type

7.2.5.3.2 Market size and forecast, by Age group

7.2.5.3.3 Market size and forecast, by End User

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Type

7.3.3 Europe Market size and forecast, by Age group

7.3.4 Europe Market size and forecast, by End User

7.3.4.1 Europe Hospitals Lung Cancer Screening Market by Type

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Type

7.3.5.1.2 Market size and forecast, by Age group

7.3.5.1.3 Market size and forecast, by End User

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by Type

7.3.5.2.2 Market size and forecast, by Age group

7.3.5.2.3 Market size and forecast, by End User

7.3.5.3 UK

7.3.5.3.1 Market size and forecast, by Type

7.3.5.3.2 Market size and forecast, by Age group

7.3.5.3.3 Market size and forecast, by End User

7.3.5.4 Italy

7.3.5.4.1 Market size and forecast, by Type

7.3.5.4.2 Market size and forecast, by Age group

7.3.5.4.3 Market size and forecast, by End User

7.3.5.5 Spain

7.3.5.5.1 Market size and forecast, by Type

7.3.5.5.2 Market size and forecast, by Age group

7.3.5.5.3 Market size and forecast, by End User

7.3.5.6 Rest of Europe

7.3.5.6.1 Market size and forecast, by Type

7.3.5.6.2 Market size and forecast, by Age group

7.3.5.6.3 Market size and forecast, by End User

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Type

7.4.3 Asia-Pacific Market size and forecast, by Age group

7.4.4 Asia-Pacific Market size and forecast, by End User

7.4.4.1 Asia-Pacific Hospitals Lung Cancer Screening Market by Type

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Type

7.4.5.1.2 Market size and forecast, by Age group

7.4.5.1.3 Market size and forecast, by End User

7.4.5.2 China

7.4.5.2.1 Market size and forecast, by Type

7.4.5.2.2 Market size and forecast, by Age group

7.4.5.2.3 Market size and forecast, by End User

7.4.5.3 Australia

7.4.5.3.1 Market size and forecast, by Type

7.4.5.3.2 Market size and forecast, by Age group

7.4.5.3.3 Market size and forecast, by End User

7.4.5.4 India

7.4.5.4.1 Market size and forecast, by Type

7.4.5.4.2 Market size and forecast, by Age group

7.4.5.4.3 Market size and forecast, by End User

7.4.5.5 South Korea

7.4.5.5.1 Market size and forecast, by Type

7.4.5.5.2 Market size and forecast, by Age group

7.4.5.5.3 Market size and forecast, by End User

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Market size and forecast, by Type

7.4.5.6.2 Market size and forecast, by Age group

7.4.5.6.3 Market size and forecast, by End User

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Type

7.5.3 LAMEA Market size and forecast, by Age group

7.5.4 LAMEA Market size and forecast, by End User

7.5.4.1 LAMEA Hospitals Lung Cancer Screening Market by Type

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by Type

7.5.5.1.2 Market size and forecast, by Age group

7.5.5.1.3 Market size and forecast, by End User

7.5.5.2 Saudi Arabia

7.5.5.2.1 Market size and forecast, by Type

7.5.5.2.2 Market size and forecast, by Age group

7.5.5.2.3 Market size and forecast, by End User

7.5.5.3 South Africa

7.5.5.3.1 Market size and forecast, by Type

7.5.5.3.2 Market size and forecast, by Age group

7.5.5.3.3 Market size and forecast, by End User

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Market size and forecast, by Type

7.5.5.4.2 Market size and forecast, by Age group

7.5.5.4.3 Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Canon Medical Systems Corporation

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Eon Health

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 FUJIFILM Holdings Corporation

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 General Electric incorporated (GE Healthcare)

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Koninklijke Philips N.V.

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Medtronic plc

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Nuance Communications, Inc.

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Penrad Technologies Inc

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Siemens AG (Siemens Healthineers AG)

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Volpara Solutions Limited

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 2. LUNG CANCER SCREENING MARKET, FOR LOW-DOSE COMPUTED TOMOGRAPHY (LDCT), BY REGION, 2021-2031 ($MILLION)

TABLE 3. LUNG CANCER SCREENING MARKET FOR LOW-DOSE COMPUTED TOMOGRAPHY (LDCT), BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. LUNG CANCER SCREENING MARKET, FOR X-RAY, BY REGION, 2021-2031 ($MILLION)

TABLE 5. LUNG CANCER SCREENING MARKET FOR X-RAY, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 6. GLOBAL LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 7. LUNG CANCER SCREENING MARKET, FOR 50 AND OLDER, BY REGION, 2021-2031 ($MILLION)

TABLE 8. LUNG CANCER SCREENING MARKET FOR 50 AND OLDER, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 9. LUNG CANCER SCREENING MARKET, FOR BELOW 50, BY REGION, 2021-2031 ($MILLION)

TABLE 10. LUNG CANCER SCREENING MARKET FOR BELOW 50, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 11. GLOBAL LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 12. LUNG CANCER SCREENING MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)

TABLE 13. LUNG CANCER SCREENING MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 14. GLOBAL HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 15. LUNG CANCER SCREENING MARKET, FOR PUBLIC, BY REGION, 2021-2031 ($MILLION)

TABLE 16. LUNG CANCER SCREENING MARKET, FOR PRIVATE, BY REGION, 2021-2031 ($MILLION)

TABLE 17. LUNG CANCER SCREENING MARKET, FOR DIAGNOSTIC CENTERS, BY REGION, 2021-2031 ($MILLION)

TABLE 18. LUNG CANCER SCREENING MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 19. LUNG CANCER SCREENING MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 20. LUNG CANCER SCREENING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 21. LUNG CANCER SCREENING MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 22. NORTH AMERICA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 23. NORTH AMERICA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 24. NORTH AMERICA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 25. NORTH AMERICA HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 26. NORTH AMERICA LUNG CANCER SCREENING MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 27. U.S. LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 28. U.S. LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 29. U.S. LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 30. CANADA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 31. CANADA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 32. CANADA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 33. MEXICO LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 34. MEXICO LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 35. MEXICO LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 36. EUROPE LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 37. EUROPE LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 38. EUROPE LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 39. EUROPE HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 40. EUROPE LUNG CANCER SCREENING MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 41. GERMANY LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 42. GERMANY LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 43. GERMANY LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 44. FRANCE LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 45. FRANCE LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 46. FRANCE LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 47. UK LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 48. UK LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 49. UK LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 50. ITALY LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 51. ITALY LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 52. ITALY LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 53. SPAIN LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 54. SPAIN LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 55. SPAIN LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 56. REST OF EUROPE LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 57. REST OF EUROPE LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 58. REST OF EUROPE LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 59. ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 60. ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 61. ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 62. ASIA-PACIFIC HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 63. ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 64. JAPAN LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 65. JAPAN LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 66. JAPAN LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 67. CHINA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 68. CHINA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 69. CHINA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 70. AUSTRALIA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 71. AUSTRALIA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 72. AUSTRALIA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 73. INDIA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 74. INDIA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 75. INDIA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 76. SOUTH KOREA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 77. SOUTH KOREA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 78. SOUTH KOREA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 79. REST OF ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 80. REST OF ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 81. REST OF ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 82. LAMEA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 83. LAMEA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 84. LAMEA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 85. LAMEA HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 86. LAMEA LUNG CANCER SCREENING MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 87. BRAZIL LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 88. BRAZIL LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 89. BRAZIL LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 90. SAUDI ARABIA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 91. SAUDI ARABIA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 92. SAUDI ARABIA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 93. SOUTH AFRICA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 94. SOUTH AFRICA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 95. SOUTH AFRICA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 96. REST OF LAMEA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 97. REST OF LAMEA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 98. REST OF LAMEA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 99.CANON MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT

TABLE 100.CANON MEDICAL SYSTEMS CORPORATION: OPERATING SEGMENTS

TABLE 101.CANON MEDICAL SYSTEMS CORPORATION: PRODUCT PORTFOLIO

TABLE 102.CANON MEDICAL SYSTEMS CORPORATION: NET SALES,

TABLE 103.CANON MEDICAL SYSTEMS CORPORATION: KEY STRATERGIES

TABLE 104.EON HEALTH: COMPANY SNAPSHOT

TABLE 105.EON HEALTH: OPERATING SEGMENTS

TABLE 106.EON HEALTH: PRODUCT PORTFOLIO

TABLE 107.EON HEALTH: NET SALES,

TABLE 108.EON HEALTH: KEY STRATERGIES

TABLE 109.FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT

TABLE 110.FUJIFILM HOLDINGS CORPORATION: OPERATING SEGMENTS

TABLE 111.FUJIFILM HOLDINGS CORPORATION: PRODUCT PORTFOLIO

TABLE 112.FUJIFILM HOLDINGS CORPORATION: NET SALES,

TABLE 113.FUJIFILM HOLDINGS CORPORATION: KEY STRATERGIES

TABLE 114.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): COMPANY SNAPSHOT

TABLE 115.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): OPERATING SEGMENTS

TABLE 116.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): PRODUCT PORTFOLIO

TABLE 117.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): NET SALES,

TABLE 118.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): KEY STRATERGIES

TABLE 119.KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT

TABLE 120.KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS

TABLE 121.KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO

TABLE 122.KONINKLIJKE PHILIPS N.V.: NET SALES,

TABLE 123.KONINKLIJKE PHILIPS N.V.: KEY STRATERGIES

TABLE 124.MEDTRONIC PLC: COMPANY SNAPSHOT

TABLE 125.MEDTRONIC PLC: OPERATING SEGMENTS

TABLE 126.MEDTRONIC PLC: PRODUCT PORTFOLIO

TABLE 127.MEDTRONIC PLC: NET SALES,

TABLE 128.MEDTRONIC PLC: KEY STRATERGIES

TABLE 129.NUANCE COMMUNICATIONS, INC.: COMPANY SNAPSHOT

TABLE 130.NUANCE COMMUNICATIONS, INC.: OPERATING SEGMENTS

TABLE 131.NUANCE COMMUNICATIONS, INC.: PRODUCT PORTFOLIO

TABLE 132.NUANCE COMMUNICATIONS, INC.: NET SALES,

TABLE 133.NUANCE COMMUNICATIONS, INC.: KEY STRATERGIES

TABLE 134.PENRAD TECHNOLOGIES INC: COMPANY SNAPSHOT

TABLE 135.PENRAD TECHNOLOGIES INC: OPERATING SEGMENTS

TABLE 136.PENRAD TECHNOLOGIES INC: PRODUCT PORTFOLIO

TABLE 137.PENRAD TECHNOLOGIES INC: NET SALES,

TABLE 138.PENRAD TECHNOLOGIES INC: KEY STRATERGIES

TABLE 139.SIEMENS AG (SIEMENS HEALTHINEERS AG): COMPANY SNAPSHOT

TABLE 140.SIEMENS AG (SIEMENS HEALTHINEERS AG): OPERATING SEGMENTS

TABLE 141.SIEMENS AG (SIEMENS HEALTHINEERS AG): PRODUCT PORTFOLIO

TABLE 142.SIEMENS AG (SIEMENS HEALTHINEERS AG): NET SALES,

TABLE 143.SIEMENS AG (SIEMENS HEALTHINEERS AG): KEY STRATERGIES

TABLE 144.VOLPARA SOLUTIONS LIMITED: COMPANY SNAPSHOT

TABLE 145.VOLPARA SOLUTIONS LIMITED: OPERATING SEGMENTS

TABLE 146.VOLPARA SOLUTIONS LIMITED: PRODUCT PORTFOLIO

TABLE 147.VOLPARA SOLUTIONS LIMITED: NET SALES,

TABLE 148.VOLPARA SOLUTIONS LIMITED: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.LUNG CANCER SCREENING MARKET SEGMENTATION

FIGURE 2.LUNG CANCER SCREENING MARKET,2021-2031

FIGURE 3.LUNG CANCER SCREENING MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.LUNG CANCER SCREENING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.LUNG CANCER SCREENING MARKET,BY TYPE,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF LOW-DOSE COMPUTED TOMOGRAPHY (LDCT) LUNG CANCER SCREENING MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF X-RAY LUNG CANCER SCREENING MARKET,2021-2031(%)

FIGURE 15.LUNG CANCER SCREENING MARKET,BY AGE GROUP,2021(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF 50 AND OLDER LUNG CANCER SCREENING MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF BELOW 50 LUNG CANCER SCREENING MARKET,2021-2031(%)

FIGURE 18.LUNG CANCER SCREENING MARKET,BY END USER,2021(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LUNG CANCER SCREENING MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC CENTERS LUNG CANCER SCREENING MARKET,2021-2031(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS LUNG CANCER SCREENING MARKET,2021-2031(%)

FIGURE 22.LUNG CANCER SCREENING MARKET BY REGION,2021

FIGURE 23.U.S. LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 24.CANADA LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 25.MEXICO LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 26.GERMANY LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 27.FRANCE LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 28.UK LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 29.ITALY LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 30.SPAIN LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 31.REST OF EUROPE LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 32.JAPAN LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 33.CHINA LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 34.AUSTRALIA LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 35.INDIA LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 36.SOUTH KOREA LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 37.REST OF ASIA-PACIFIC LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 38.BRAZIL LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 39.SAUDI ARABIA LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 40.SOUTH AFRICA LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 41.REST OF LAMEA LUNG CANCER SCREENING MARKET,2021-2031($MILLION)

FIGURE 42. TOP WINNING STRATEGIES, BY YEAR

FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 46.COMPETITIVE DASHBOARD

FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 48.CANON MEDICAL SYSTEMS CORPORATION.: NET SALES ,($MILLION)

FIGURE 49.EON HEALTH.: NET SALES ,($MILLION)

FIGURE 50.FUJIFILM HOLDINGS CORPORATION.: NET SALES ,($MILLION)

FIGURE 51.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE).: NET SALES ,($MILLION)

FIGURE 52.KONINKLIJKE PHILIPS N.V..: NET SALES ,($MILLION)

FIGURE 53.MEDTRONIC PLC.: NET SALES ,($MILLION)

FIGURE 54.NUANCE COMMUNICATIONS, INC..: NET SALES ,($MILLION)

FIGURE 55.PENRAD TECHNOLOGIES INC.: NET SALES ,($MILLION)

FIGURE 56.SIEMENS AG (SIEMENS HEALTHINEERS AG).: NET SALES ,($MILLION)

FIGURE 57.VOLPARA SOLUTIONS LIMITED.: NET SALES ,($MILLION